PE20230181A1 - USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS - Google Patents

USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS

Info

Publication number
PE20230181A1
PE20230181A1 PE2022000980A PE2022000980A PE20230181A1 PE 20230181 A1 PE20230181 A1 PE 20230181A1 PE 2022000980 A PE2022000980 A PE 2022000980A PE 2022000980 A PE2022000980 A PE 2022000980A PE 20230181 A1 PE20230181 A1 PE 20230181A1
Authority
PE
Peru
Prior art keywords
reboxetine
nervous system
system disorders
treat nervous
esreboxetine
Prior art date
Application number
PE2022000980A
Other languages
Spanish (es)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/740,329 external-priority patent/US20200147093A1/en
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Priority claimed from PCT/US2020/062560 external-priority patent/WO2021113163A1/en
Publication of PE20230181A1 publication Critical patent/PE20230181A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

En el presente documento se describen los metodos para el tratamiento de la narcolepsia con cataplexia, los cuales comprenden la administracion de la reboxetina (la que incluye la esreboxetina) a un ser humano que lo necesite. La reboxetina (la que incluye la esreboxetina) tambien se puede utilizar en la elaboracion de un medicamento para el tratamiento de la narcolepsia con cataplexia. Tambien se dan a conocer en este documento los kits que comprenden una composicion farmaceutica que comprende la reboxetina (la que incluye la esreboxetina) y las instrucciones para usar la composicion farmaceutica para el tratamiento de la narcolepsia con cataplexia en un ser humano.Described herein are methods for the treatment of narcolepsy with cataplexy, which comprise administering reboxetine (including esreboxetine) to a human in need thereof. Reboxetine (which includes esreboxetine) can also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (which includes esreboxetine) and instructions for using the pharmaceutical composition for the treatment of cataplexy narcolepsy in a human.

PE2022000980A 2019-12-03 2020-11-30 USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS PE20230181A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962943077P 2019-12-03 2019-12-03
US201962946295P 2019-12-10 2019-12-10
US16/740,329 US20200147093A1 (en) 2018-10-15 2020-01-10 Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US16/740,409 US11351175B2 (en) 2018-10-15 2020-01-11 Use of reboxetine to treat narcolepsy
US16/740,410 US20200147095A1 (en) 2018-10-15 2020-01-11 Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US16/740,411 US20200147096A1 (en) 2018-10-15 2020-01-11 Use of esreboxetine to treat nervous system disorders such as fibromyalgia
PCT/US2020/062560 WO2021113163A1 (en) 2019-12-03 2020-11-30 Use of reboxetine to treat nervous system disorders

Publications (1)

Publication Number Publication Date
PE20230181A1 true PE20230181A1 (en) 2023-02-01

Family

ID=81851750

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000980A PE20230181A1 (en) 2019-12-03 2020-11-30 USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS

Country Status (12)

Country Link
EP (1) EP4069244A4 (en)
JP (1) JP2023504685A (en)
KR (1) KR20220108122A (en)
CN (1) CN114746097A (en)
AU (1) AU2020395082A1 (en)
BR (1) BR112022010677A2 (en)
CA (1) CA3163505A1 (en)
CO (1) CO2022007507A2 (en)
CR (1) CR20220247A (en)
IL (1) IL293536A (en)
MX (1) MX2022006630A (en)
PE (1) PE20230181A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1969859A (en) * 1999-07-01 2007-05-30 法玛西雅厄普约翰美国公司 Norepinephrine reuptake inhibitors and methods of using the same
DE60022916T2 (en) * 1999-07-01 2006-07-06 Pharmacia & Upjohn Co. Llc, Kalamazoo Reboxetine for the treatment of peripheral neuropathies
CA2686723A1 (en) * 2007-05-07 2008-11-13 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
PT2968208T (en) * 2013-03-13 2022-10-28 Aerial Biopharma Llc Treatment of cataplexy

Also Published As

Publication number Publication date
CO2022007507A2 (en) 2022-06-21
CA3163505A1 (en) 2021-06-10
IL293536A (en) 2022-08-01
KR20220108122A (en) 2022-08-02
CN114746097A (en) 2022-07-12
BR112022010677A2 (en) 2022-08-16
JP2023504685A (en) 2023-02-06
MX2022006630A (en) 2022-06-24
EP4069244A4 (en) 2023-12-20
CR20220247A (en) 2022-08-18
EP4069244A1 (en) 2022-10-12
AU2020395082A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
CL2022001743A1 (en) Gamma-Hydroxybutyrate (GHB) Dosage
MX2020004467A (en) Methods for treating or preventing asthma by administering an il-4r antagonist.
GT201700246A (en) METHODS AND KITS TO TREAT DEPRESSION
CL2021000924A1 (en) Use of reboxetine for the treatment of narcolepsy
CO2017012381A2 (en) Mono or disubstituted indole derivatives as inhibitors of dengue viral replication
CO2019000938A2 (en) Nmda spiro-lactam modulators and methods of use thereof
AR107871A1 (en) COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS
CO2019000944A2 (en) Modulators of the nmda spiro-lactam and bis-spiro-lactam receptor and use thereof
CO2019000945A2 (en) Modulators of the nmda spiro-lactam receptor and use thereof
CL2019000247A1 (en) Modulators of the nmda spiro-lactam receptor and use thereof.
CO2021015793A2 (en) Methods of treating or preventing asthma by administering an il-33 antagonist
CL2019002218A1 (en) Triple combination formulations and methods to treat or reduce the risk of cardiovascular disease.
BR112017006113A8 (en) Auristatin uses, pharmaceutical compositions, dosage forms for cancer treatment and kits.
CL2021002646A1 (en) Methods and compositions for use in the treatment of cancer without psychoactive effects
CO2022007814A2 (en) Tyk2 pseudokinase ligands
BR112022007721A2 (en) METHOD FOR THE TREATMENT OF DEMENTIA
CO2022014499A2 (en) nlrp3 modulators
CO2020007601A2 (en) Modified brucella vaccine strain for the treatment of brucellosis
CL2020000508A1 (en) Anti-egfr drug-antibody (adc) conjugates and their uses.
CL2020000270A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor.
MX2020004513A (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same.
BR112019004540A2 (en) method for treating dementia in a patient, pharmaceutical composition, method for treating dementia in a patient, method for reducing the likelihood of developing dementia in a patient, composition for use in treating dementia in a patient, composition and composition for use in reducing dementia likelihood of developing dementia in a patient undergoing long therapy with a non-steroidal anti-inflammatory drug or aspirin
CR20220250A (en) METHODS FOR THE TREATMENT OF DEPRESSIVE DISORDERS
PE20230181A1 (en) USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS
CL2022001476A1 (en) Use of reboxetine to treat disorders of the nervous system